Figure 2
From: Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis
Percentage of monocyte subsets in patients with RA at baseline and over anti-TNFα treatment. Panel A represents flow cytometry analysis of circulating monocytes from a representative patient. The percentage of circulating CD14+highCD16- (panel B), CD14+highCD16+ (panel C) and CD14+lowCD16+ monocytes (panel D) of non-responder (□) and responders (○) at baseline and after three and six months of MTX treatment, and those of healthy controls (▼), are shown as mean ± SEM. * significant difference between patients with RA and healthy controls. † significant difference between non-responders and responders. ‡ significant difference between baseline and six-month values.